TY - JOUR AU - Rawla, P. PY - 2019 DA - 2019// TI - Epidemiology of prostate cancer JO - World J Oncol VL - 10 UR - https://doi.org/10.14740/wjon1191 DO - 10.14740/wjon1191 ID - Rawla2019 ER - TY - JOUR AU - Ross, J. S. AU - Sheehan, C. E. AU - Fisher, H. A. G. PY - 2003 DA - 2003// TI - Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer JO - Clin Cancer Res VL - 9 ID - Ross2003 ER - TY - JOUR AU - Afshar-Oromieh, A. AU - Malcher, A. AU - Eder, M. PY - 2013 DA - 2013// TI - PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions JO - Eur J Nucl Med Mol Imaging VL - 40 UR - https://doi.org/10.1007/s00259-012-2298-2 DO - 10.1007/s00259-012-2298-2 ID - Afshar-Oromieh2013 ER - TY - JOUR AU - Chang, S. S. PY - 2004 DA - 2004// TI - Overview of prostate-specific membrane antigen JO - Rev Urol VL - 6 ID - Chang2004 ER - TY - JOUR AU - Afshar-Oromieh, A. AU - Holland-Letz, T. AU - Giesel, F. L. PY - 2017 DA - 2017// TI - Diagnostic performance of68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients JO - Eur J Nucl Med Mol Imaging VL - 44 UR - https://doi.org/10.1007/s00259-017-3711-7 DO - 10.1007/s00259-017-3711-7 ID - Afshar-Oromieh2017 ER - TY - JOUR AU - Eiber, M. AU - Maurer, T. AU - Souvatzoglou, M. PY - 2015 DA - 2015// TI - Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy JO - J Nucl Med VL - 56 UR - https://doi.org/10.2967/jnumed.115.154153 DO - 10.2967/jnumed.115.154153 ID - Eiber2015 ER - TY - JOUR AU - Perera, M. AU - Papa, N. AU - Christidis, D. PY - 2016 DA - 2016// TI - Sensitivity, specificity, and predictors of positive (68)Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis JO - Eur Urol VL - 70 UR - https://doi.org/10.1016/j.eururo.2016.06.021 DO - 10.1016/j.eururo.2016.06.021 ID - Perera2016 ER - TY - JOUR AU - Fendler, W. P. AU - Calais, J. AU - Eiber, M. PY - 2019 DA - 2019// TI - Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial JO - JAMA Oncol VL - 5 UR - https://doi.org/10.1001/jamaoncol.2019.0096 DO - 10.1001/jamaoncol.2019.0096 ID - Fendler2019 ER - TY - STD TI - Hope TA, Fayad ZA, Fowler KJ, et al. Summary of the first ISMRM-SNMMI workshop on PET/MRI: applications and limitations. J Nucl Med. 2019. pp. 1340–1346. ID - ref9 ER - TY - JOUR AU - Rooij, M. AU - Hamoen, E. H. AU - Fütterer, J. J. AU - Barentsz, J. O. AU - Rovers, M. M. PY - 2014 DA - 2014// TI - Accuracy of multiparametric MRI for prostate cancer detection: a meta-analysis JO - AJR Am J Roentgenol VL - 202 UR - https://doi.org/10.2214/AJR.13.11046 DO - 10.2214/AJR.13.11046 ID - Rooij2014 ER - TY - JOUR AU - Afshar-Oromieh, A. AU - Haberkorn, U. AU - Schlemmer, H. P. PY - 2014 DA - 2014// TI - Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience JO - Eur J Nucl Med Mol Imaging VL - 41 UR - https://doi.org/10.1007/s00259-013-2660-z DO - 10.1007/s00259-013-2660-z ID - Afshar-Oromieh2014 ER - TY - JOUR AU - Lake, S. T. AU - Greene, K. L. AU - Westphalen, A. C. PY - 2017 DA - 2017// TI - Optimal MRI sequences for 68Ga-PSMA-11 PET/MRI in evaluation of biochemically recurrent prostate cancer JO - EJNMMI Res VL - 7 UR - https://doi.org/10.1186/s13550-017-0327-7 DO - 10.1186/s13550-017-0327-7 ID - Lake2017 ER - TY - JOUR AU - Bailey, J. J. AU - Jordan, E. J. AU - Burke, C. PY - 2018 DA - 2018// TI - Does extended PET acquisition in PET/MRI rectal cancer staging improve results? JO - Am J Roentgenol VL - 211 UR - https://doi.org/10.2214/AJR.18.19620 DO - 10.2214/AJR.18.19620 ID - Bailey2018 ER - TY - JOUR AU - Lütje, S. AU - Blex, S. AU - Gomez, B. PY - 2016 DA - 2016// TI - Optimization of acquisition time of 68Ga-PSMA-ligand PET/MRI in patients with local and metastatic prostate cancer JO - PLoS ONE VL - 11 UR - https://doi.org/10.1371/journal.pone.0164392 DO - 10.1371/journal.pone.0164392 ID - Lütje2016 ER - TY - JOUR AU - Noto, B. AU - Buther, F. AU - Springe, K. A. PY - 2017 DA - 2017// TI - Impact of PET acquisition durations on image quality and lesion detectability in whole-body 68Ga-PSMA PET-MRI JO - EJNMMI Res VL - 7 UR - https://doi.org/10.1186/s13550-017-0261-8 DO - 10.1186/s13550-017-0261-8 ID - Noto2017 ER - TY - JOUR AU - Hope, T. A. AU - Aggarwal, R. AU - Chee, B. PY - 2017 DA - 2017// TI - Impact of 68Ga-PSMA-11 PET on management in patients with biochemically recurrent prostate cncer. J Nucl med JO - Soc Nuclear Med VL - 58 UR - https://doi.org/10.2967/jnumed.117.192476 DO - 10.2967/jnumed.117.192476 ID - Hope2017 ER - TY - JOUR AU - Jakoby, B. W. AU - Bercier, Y. AU - Conti, M. AU - Casey, M. E. AU - Bendriem, B. AU - Townsend, D. W. PY - 2011 DA - 2011// TI - Physical and clinical performance of the mCT time-of-flight PET/CT scanner JO - Phys Med Biol VL - 56 UR - https://doi.org/10.1088/0031-9155/56/8/004 DO - 10.1088/0031-9155/56/8/004 ID - Jakoby2011 ER - TY - STD TI - Fendler WP, Eiber M, Beheshti M, et al. 68Ga-PSMA PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. 3rd ed. 2017;44:1014–1024. ID - ref18 ER - TY - JOUR AU - Hohberg, M. AU - Kobe, C. AU - Täger, P. PY - 2019 DA - 2019// TI - Combined early and late [68Ga]PSMA-HBED-CC PET scans improve lesion detectability in biochemical recurrence of prostate cancer with low PSA levels JO - Mol Imaging Biol VL - 21 UR - https://doi.org/10.1007/s11307-018-1263-2 DO - 10.1007/s11307-018-1263-2 ID - Hohberg2019 ER - TY - JOUR AU - Schmuck, S. AU - Nordlohne, S. AU - Klot, C. A. PY - 2017 DA - 2017// TI - Comparison of standard and delayed imaging to improve the detection rate of [68Ga]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer JO - Eur J Nucl Med Mol Imaging VL - 44 UR - https://doi.org/10.1007/s00259-017-3669-5 DO - 10.1007/s00259-017-3669-5 ID - Schmuck2017 ER - TY - JOUR AU - Werner, R. A. AU - Derlin, T. AU - Lapa, C. PY - 2020 DA - 2020// TI - 18F-labeled, PSMA-targeted radiotracers: leveraging the advantages of radiofluorination for prostate cancer molecular imaging JO - Theranostics. VL - 10 UR - https://doi.org/10.7150/thno.37894 DO - 10.7150/thno.37894 ID - Werner2020 ER - TY - JOUR AU - Dietlein, M. AU - Kobe, C. AU - Kuhnert, G. PY - 2015 DA - 2015// TI - Comparison of [(18)F]DCFPyL and [(68)Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer JO - Mol Imaging Biol VL - 17 UR - https://doi.org/10.1007/s11307-015-0866-0 DO - 10.1007/s11307-015-0866-0 ID - Dietlein2015 ER -